Past EFORT Congress Exhibitions
PAST EFORT CONGRESS EXHIBITIONS
EFORT understands that in order to assess the relevance of your company exhibiting during 21st EFORT Congress Vienna 2020 – it is often useful to see which companies have exhibited at previous EFORT congresses. For your convenience, therefore, please find the complete exhibitor listings for the following annual congresses via the links below:
- 20th EFORT Annual Congress Lisbon 2019 Exhibitors database.
- 19th EFORT Annual Congress Barcelona 2018 Exhibitors database.
- 18th EFORT Annual Congress Vienna 2017 Exhibitors database.
- 17th EFORT Annual Congress Geneva 2016 Exhibitors database.
- 16th EFORT Annual Congress Prague 2015 Exhibitors database.
- 15thEFORT Annual Congress London 2014 Exhibitors database.
- 14th EFORT Annual Congress Istanbul 2013 Exhibitors database.
For any enquiries relating to exhibition, satellites and sponsorship – please contact by using the official exhibitors and sponsorship contact us online form.
Exhibitors Database 2020
EFORT invites you to browse through the Exhibitors Database of the 21st EFORT Annual Congress Vienna 2020 which represents those exhibitors that have already committed to and confirmed their presence at the 2020 EFORT Congress to be held in Vienna, Austria, from 10 to 12 June 2020.
EFORT Industry Database
Maxigen Biotech Inc.
Maxigen Biotech Inc. (MBI) was founded in December 1998. Next year, MBI stationed in National Yang-Ming University and set up an incubation center at there to conduct the R&D work of collagen. In June,2002, Global Investment Holdings made capital investment for MBI and became one of the shareholders. In the Decemeber of same year, MBI started building its own biomedical factory office building at Wugu industrial park. Next year, MBI set up the skin care product facility in Sigang township, Tainan county. MBI utilizes its core competence in biopolymers and has developed a broad range of applications in areas such as medical devices and skincare products. MBI specializes in the developing, manufacturing, and marketing of biomedical and skincare products. Headquarters was moved to Hwa-Ya Technologypark in July, 2016. Our major shareholders include GIH Group, Mega International Commercial Bank, First Financial Holding, Shanghai Fuson Pharmaceutical Group Company and – NuVasive Inc., Nasdaq-listed medical device company in the US.
MBI's Biomedical facility is certified by Taiwan GMP, ISO13485 and Korean KGMP. Furthermore, it passed US FDA inspection in 2009 and 2015 with no significant deviation being observed. MBI's biomedical products are mainly applied to the usage of orthopedics, aesthetic medicine, dental and ophthalmology. Production quality is in accordance with international regulations and requirements. Also our products have been certified by Taiwan, China, USA, Europe, Southeast Asia, Middle East and other emerging markets.
MBI's Skincare Product Division specializes in the design of various types of unique formulations and it has an ISO 22716 and GMP certified manufacturing facility. Skincare division provides the most effective and reliable cosmetic products to meet the needs of various skin types. We OEM for many well known global brands as well as Taiwan domestic ones.These products including various kinds of mask series, cleansing series, skin care series, hair care series and body care series. These Products are well received and marketed all over the world.
Benefit from the core competence of biotech division, skin care R&D center also has its own proprietary development capabilities, such as the development of platinum, gold particles conductive technology raw materials "double gold crystal peptide". This is combined with our own proprietary manufacturing know-how of collagen and hyaluronic acid, therefore we are capable of developing anti-aging wrinkle, low sensitivity, moisturizing, whitening and other innovative products series for the skin regeneration and repair with more efficacy. In addition, MBI also works closely with the internationally well-known institutions then to introduce new technology collaboration and commercialization, to make the skin young, elastic again.